Innovation Pharmaceuticals Inc (IPIX)

[run256]

Based in the xenograft models K (200 mg/kg) proved to be more effective than paclitaxel (22 mg/Kg)

With regards to paclitaxel dosing:

Activity for paclitaxel 135 mg/m2 and 200 mg/m2 by 1-hour infusion every 3 weeks in patients with NSCLC, with minimal myelosuppression and the suggestion of a dose-response relationship, has been reported. In November 1994, we initiated a phase II trial in patients with advanced, measurable, chemotherapy-naive NSCLC using paclitaxel 175 mg/m2 given in 1 hour, and carboplatin dosed to a fixed target area under the concentration-time curve of 7.5 every 3 weeks. In the absence of grade 4 myelosuppression, paclitaxel was escalated on an intrapatient basis by 35 mg/m2 per cycle to a maximum dose of 280 mg/m2 by cycle 4.

Kevetrin:
The dosing was been increased approximately 33 percent from the seventh cohort to 215 mg/m2.

At the end of day models are just guidelines to be taken with a grain of salt and maybe because of K very short 1/2 life and non-genotoxic properties this will allow it to dose patients more frequently, maybe the MTD is still far away . But I see your point with regards to efficacy vs current dosing escalation.